Navigation Links
European Neurologists Expect Significant Increases in the Use of Both Tysabri and Extavia in Their Multiple Sclerosis Patients the Next Six Months, According to a Recent Report From BioTrends
Date:12/21/2010

EXTON, Pa., Dec. 21, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that while neurologists in the EU tend to prescribe the established interferon betas as their first line disease modifying agents (DMAs) for the treatment of multiple sclerosis (MS) patients, they are most satisfied with Biogen/Elan's Tysabri. Prescribing of both Tysabri and Novartis's recently launched DMA, Extavia, is anticipated to increase over the next six months with Bayer's Betaferon suffering the most in terms of market share loss. Despite these expected changes, neurologists clearly associate most of the DMAs with a certain MS patient type and their reported prescribing reflects these preference patterns.

The recently released TreatmentTrends®: Multiple Sclerosis in the European Union report finds that neurologists in the U.K. have less clinical experience with many of the DMAs, prescribe DMAs to a smaller percentage of their MS patients, and are detailed less than their counterparts in France, Germany, Italy and Spain. In line with these regional differences, neurologists in the U.K. report relying on different attributes when making their DMA prescribing decisions and identify different unmet needs for DMAs in development compared to neurologists from the other EU regions.

Among the eight therapies in development that were profiled in the research, interest is rated highest for Novartis's Gilenya and Merck Serono's Movectro -- despite the recent nonapproval by the European Medicines Agency for the latter product which Merck has recently appealed. Neurologists in the U.K. again diverge in their reported interest in the DMAs in development with a greater level of enthusiasm for Genzyme/Bayer's alemtuzumab compared to their counterparts in the other EU regions. While familiarity and interest is currently low for Biogen's PEG-Avonex and BG-12, Teva's laquinimod, Sanofi-Aventis's teriflunomide and Abbott/Biogen's daclizumab, for some of these DMAs in de
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015  Mirati Therapeutics, ... focusing on genetic and epigenetic drivers of cancer, will be ... August 11, 2015 at 1:55 p.m. ET (10:55 a.m. PT) ... Baum , M.D., Ph.D., president and CEO of Mirati, will ... of the presentation will be accessible on the "Investors" page ...
(Date:8/3/2015)... 2015   The Intellectual Property and Science ... provider of intelligent information for businesses and professionals ... Pharmaceutical R&D Factbook , the biopharmaceutical industry,s leading ... declines in R&D, the analysis identifies a surge ... and forecasts sales to reach $1.3 trillion by ...
Breaking Medicine Technology:Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3Pharma Sales to Grow Beyond $1 Trillion 2
... June 21, 2010 ReportsandReports announces it Will,Carry Cardiovascular Devices Market ... , , ... http://www.reportsandreports.com/market-reports/netherlands-cardiovascular-de ,vices-market-outlook-to-2016/) , , , ... (Due to the length of these URLs, it may be necessary to copy ...
... AHMEDABAD, India , June 21, 2010 ... healthcare companies has,received Phase I clinical trial permission from the DCGI for ... Centre using a,unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule. ... ...
Cached Medicine Technology:Cardiovascular Devices Market Outlook June Update by ReportsandReports 2Cardiovascular Devices Market Outlook June Update by ReportsandReports 3Cardiovascular Devices Market Outlook June Update by ReportsandReports 4Cardiovascular Devices Market Outlook June Update by ReportsandReports 5Cardiovascular Devices Market Outlook June Update by ReportsandReports 6Cardiovascular Devices Market Outlook June Update by ReportsandReports 7Cardiovascular Devices Market Outlook June Update by ReportsandReports 8Cardiovascular Devices Market Outlook June Update by ReportsandReports 9Cardiovascular Devices Market Outlook June Update by ReportsandReports 10Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 2Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 3
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... the launch of a new product suite designed to provide pharmaceutical and healthcare ... trends based on multi-sourced and cross-referenced data from regulatory filings (including the FDA ...
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... Updated enrollment data on the top U.S. health ... be accessed at http://www.AISHealth.com . The data is free to all registered users ... tables and charts on the website’s “Data” section include:, , ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental ... and crafts, toys, novelties, and school supplies, has developed engaging and affordable teacher ... exclusive collection includes student rewards, classroom decorations, crafts and educational resources featuring ...
(Date:8/4/2015)... ... 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving Ohio ... Well videos to preparing high school athletes for fall sports. , In a concise video ... , What steps to take to help prevent injuries , ...
Breaking Medicine News(10 mins):Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 2Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2
... HealthDay Reporter , TUESDAY, Sept. 6 (HealthDay News) ... as ibuprofen during the first stage of their pregnancy ... suggests. "We,re seeing a 2.4-fold increased risk ... pregnancy," said Anick Berard, senior author of a paper ...
... U.S. Food and Drug Administration (FDA) clears the path for ... estimating the risk of ovarian cancer in women with a ... and use of a combination of blood tests for proteins ... (ROMA). Research demonstrates that examining levels of HE4 and CA125 ...
... PARK, Md. - Amid ongoing concerns about E. coli, ... take a unique approach to make imports bound for ... those foods intensive, hands-on lab training in U.S. government ... "The more we can get foreign food facilities ...
... German . The stomach bacterium Helicobacter pylori ... gastric cancer, the third most common cause of cancer-related deaths in ... identified a mechanism of Helicobacter pylori that damages the DNA of ... transformation. Gastric cancer is one of the most common and ...
... cells is an effective treatment for patients with malignant ... cells are crucial to the outcome. Researchers from Lund ... the quality of the transplanted cells using ultrasound for ... blood stem cell transplant is often the only treatment ...
... , This release is available in German . ... they react with a suitable behavioural response and do not ... is the case, for example, with patients who suffer from ... from the Max Planck Institute of Psychiatry have discovered two ...
Cached Medicine News:Health News:NSAIDs May Raise Miscarriage Risk: Study 2Health News:NSAIDs May Raise Miscarriage Risk: Study 3Health News:FDA clears biomarker test for ovarian cancer 2Health News:FDA clears biomarker test for ovarian cancer 3Health News:For safer food imports, Teach foreign lab workers US requirements 2Health News:For safer food imports, Teach foreign lab workers US requirements 3Health News:Stomach bacterium damages human DNA 2Health News:Ultrasound improves stem cell transplants 2Health News:Control of fear in the brain decoded 2Health News:Control of fear in the brain decoded 3
... Cost-effective, portable, continuous, or spot ... with alarms and an internal ... and Sleep Study modes make ... the hospital or clinical environment; ...
... The Autocorr Plus, the fourth ... cost-effective, versatile pulse oximeter/ECG/Respiration Monitor, with ... detect/reject, digital oximetry with SAC (Serial ... high-resolution electroluminescent screen display provides two ...
... Management Program is a Windows based, easy-to-use ... Hand-Held Pulse Oximeter. Using the Smiths ... it rapidly downloads information collected during sleep ... and assists in the Clinician's interpretation by ...
The automated and pivoting M2 hand-piece incorporates two powerful, independent electric motors : one controls the blade oscillation at 15,000 RPM and the second controls the high-torque advance of t...
Medicine Products: